Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome


Por: Sanchez, A, Roos, VH, Navarro, M, Pineda, M, Caballol, B, Moreno, L, Carballal, S, Rodriguez-Alonso, L, Cajal, TRY, Llort, G, Pinol, V, Lopez-Fernandez, A, Salces, I, Pico, MD, Rivas, L, Bujanda, L, Garzon, M, Pizarro, A, de Castro, EM, Lopez-Arias, MJ, Poves, C, Garau, C, Rodriguez-Alcalde, D, Herraiz, M, Alvarez-Urrutia, C, Dacal, A, Carrillo-Palau, M, Cid, L, Ponce, M, Barreiro-Alonso, E, Saperas, E, Aguirre, E, Romero, C, Bastiaansen, B, Gonzalez-Acosta, M, Morales-Romero, B, Ocana, T, Rivero-Sanchez, L, Jung, G, Bessa, X, Cubiella, J, Jover, R, Rodriguez-Moranta, F, Balmana, J, Brunet, J, Castells, A, Dekker, E, Capella, G, Serra-Burriel, M, Moreira, L, Pellise, M, Balaguer, F

Publicada: 1 mar 2022
Resumen:
BACKGROUND & AIMS: Colonoscopy reduces colorectal cancer (CRC) incidence and mortality in Lynch syndrome (LS) carriers. However, a high incidence of postcolonoscopy CRC (PCCRC) has been reported. Colonoscopy is highly dependent on endoscopist skill and is subject to quality variability. We aimed to evaluate the impact of key colonoscopy quality indicators on adenoma detection and prevention of PCCRC in LS. METHODS: We conducted a multicenter study focused on LS carriers without previous CRC undergoing colonoscopy surveillance (n = 893). Incident colorectal neoplasia during surveillance and quality indicators of all colonoscopies were analyzed. We performed an emulated target trial comparing the results from the first and second surveillance colonoscopies to assess the effect of colonoscopy quality indicators on adenoma detection and PCCRC incidence. Risk analyses were conducted using a multivariable logistic regression model. RESULTS: The 10-year cumulative incidence of adenoma and PCCRC was 60.6% (95% CI, 55.5%-65.2%) and 7.9% (95% CI, 5.2%-10.6%), respectively. Adequate bowel preparation (odds ratio [OR], 2.07; 95% CI, 1.06-4.3), complete colonoscopies (20% vs 0%; P = .01), and panchromoendoscopy use (OR, 2.14; 95% CI, 1.15-3.95) were associated with significant improvement in adenoma detection. PCCRC risk was significantly lower when colonoscopies were performed during a time interval of less than every 3 years (OR, 0.35; 95% CI, 0.14-0.97). We observed a consistent but not significant reduction in PCCRC risk for a previous complete examination (OR, 0.16; 95% CI, 0.03-1.28), adequate bowel preparation (OR, 0.64; 95% CI, 0.17-3.24), or previous use of high-definition colonoscopy (OR, 0.37; 95% CI, 0.02-2.33). CONCLUSIONS: Complete colonoscopies with adequate bowel preparation and chromoendoscopy use are associated with improved adenoma detection, while surveillance intervals of less than 3 years are associated with a reduction of PCCRC incidence. In LS, high-quality colonoscopy surveillance is of utmost importance for CRC prevention.

Filiaciones:
Sanchez, A:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Roos, VH:
 Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

Navarro, M:
 Hosp Duran & Reynals, Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Hereditary Canc Program, Barcelona, Spain

Pineda, M:
 Hosp Duran & Reynals, Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Hereditary Canc Program, Barcelona, Spain

Caballol, B:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Moreno, L:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Carballal, S:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Rodriguez-Alonso, L:
 Hosp Univ Bellvitge, Dept Gastroenterol, Catalan Inst Oncol, Barcelona, Spain

Cajal, TRY:
 Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain

Llort, G:
 Parc Tauli Hosp Univ, Dept Med Oncol & Gastroenterol, Conscorci Sanitari Terrasa, Sabadell Terrasa, Spain

Pinol, V:
 Univ Girona, Hosp Dr Josep Trueta, Dept Gastroenterol, Girona, Girona, Spain

Lopez-Fernandez, A:
 Vall Hebron Inst Oncol, Dept Med Oncol, Hereditary Canc Genet Grp, Barcelona, Spain

Salces, I:
 Hosp 12 Octubre, Dept Gastroenterol, Madrid, Spain

Pico, MD:
 Hosp Gen Univ Elche, Inst Invest Sanitaria & Biomed Alicante ISABIAL, Dept Gastroenterol, Elche, Spain

Rivas, L:
 Complexo Hosp Univ Orense, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria Galicia Sur, Dept Gastroenterol, Orense, Spain

Bujanda, L:
 Univ Basque Country, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Biodonostia Hlth Res Inst, Dept Gastroenterol,Euskal Herriko Unibertsitatea, San Sebastian, Spain

Garzon, M:
 Hosp Virgen Rocio, Dept Gastroenterol, Seville, Spain

Pizarro, A:
 Hosp Virgen Rocio, Dept Gastroenterol, Seville, Spain

de Castro, EM:
 Hosp Univ Marques Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Dept Med Oncol & Gastroenterol, Santander, Spain

Lopez-Arias, MJ:
 Hosp Univ Marques Valdecilla, Inst Invest Sanitaria Valdecilla IDIVAL, Dept Med Oncol & Gastroenterol, Santander, Spain

Poves, C:
 Hosp Clin San Carlos, Dept Gastroenterol, Madrid, Spain

Garau, C:
 Hosp Univ Son Llatzer, Dept Gastroenterol, Palma De Mallorca, Spain

Rodriguez-Alcalde, D:
 Hosp Mostoles, Dept Gastroenterol, Mostoles, Spain

Herraiz, M:
 Clin Univ Navarra, Dept Gastroenterol, Pamplona, Spain

Alvarez-Urrutia, C:
 Barcelona Hosp Mar, Inst Hosp Mar Invest Biomed IMIM, Hosp Mar Med Res Inst, Dept Gastroenterol, Barcelona, Spain

Dacal, A:
 Hosp Univ Lucus Augusti, Dept Gastroenterol, Lugo, Spain

Carrillo-Palau, M:
 Hosp Univ Canarias, Dept Gastroenterol, Tenerife, Spain

Cid, L:
 SERGAS Univ Vigo UVIGO, Inst Invest Sanitaria Galicia Sur IISGS, Serv Galego Saude SERGAS,Res Grp Digest Dis, Dept Gastroenterol,Xerencia Xest Integrada Vigo, Vigo, Spain

Ponce, M:
 Hosp Univ Fe Valencia, Dept Gastroenterol, Valencia, Spain

Barreiro-Alonso, E:
 Hosp Univ Cent Asturias, Inst Invest Sanitaria Principado Asturias, Dept Gastroenterol, Oviedo, Spain

Saperas, E:
 Univ Int Catalunya, Hosp Univ Gen Catalunya, Sch Med, Dept Gastroenterol, Barcelona, Spain

Aguirre, E:
 Hosp Quironsalud Zaragoza, Dept Med Oncol, Genet Counseling Unit, Zaragoza, Spain

Romero, C:
 Parc Tauli Hosp Univ, Dept Med Oncol & Gastroenterol, Conscorci Sanitari Terrasa, Sabadell Terrasa, Spain

 Hospital de la Santa Creu i Sant Pau, Barcelona, Spain

Bastiaansen, B:
 Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

Gonzalez-Acosta, M:
 Hosp Duran & Reynals, Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Hereditary Canc Program, Barcelona, Spain

Morales-Romero, B:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Ocana, T:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Rivero-Sanchez, L:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Jung, G:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Bessa, X:
 Barcelona Hosp Mar, Inst Hosp Mar Invest Biomed IMIM, Hosp Mar Med Res Inst, Dept Gastroenterol, Barcelona, Spain

Cubiella, J:
 Complexo Hosp Univ Orense, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Sanitaria Galicia Sur, Dept Gastroenterol, Orense, Spain

Jover, R:
 Hosp Gen Univ Alicante, Inst Invest Biomed ISABIAL, Dept Gastroenterol, Alicante, Spain

Rodriguez-Moranta, F:
 Hosp Univ Bellvitge, Dept Gastroenterol, Catalan Inst Oncol, Barcelona, Spain

Balmana, J:
 Vall Hebron Inst Oncol, Dept Med Oncol, Hereditary Canc Genet Grp, Barcelona, Spain

Brunet, J:
 Univ Girona, Hosp Dr Josep Trueta, Sch Med,Inst Invest Biomed Giron Dr Josep Trueta, Catalan Inst Oncol,Hereditary Canc Program,Med Sc, Girona, Spain

Castells, A:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Dekker, E:
 Univ Amsterdam, Amsterdam Univ Med Ctr, Canc Ctr Amsterdam, Dept Gastroenterol & Hepatol, Amsterdam, Netherlands

Capella, G:
 Hosp Duran & Reynals, Inst Invest Biomed Bellvitge IDIBELL, Oncobell Program, Hereditary Canc Program, Barcelona, Spain

Serra-Burriel, M:
 Univ Pompeu Fabra, Ctr Res Hlth & Econ, Barcelona, Spain

Moreira, L:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Pellise, M:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain

Balaguer, F:
 Univ Barcelona, Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Inst Invest Biomed August Pi I Sunyer,Dept Gastro, Barcelona, Spain
ISSN: 15423565





Clinical Gastroenterology and Hepatology
Editorial
ELSEVIER SCIENCE INC, STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 20 Número: 3
Páginas: 611-6219
WOS Id: 000754719700016
ID de PubMed: 33157315

MÉTRICAS